Nemolizumab

Nemolizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetInterleukin-31 receptor A
Clinical data
Trade namesNemluvio
Other namesCIM-331, CD14152, nemolizumab-ilto
AHFS/Drugs.comMonograph
MedlinePlusa624059
License data
Routes of
administration		Subcutaneous injection
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismProteolytic enzymes
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG

Nemolizumab, sold under the brand name Nemluvio, is a humanized monoclonal antibody used for the treatment of prurigo nodularis and atopic dermatitis.[1] It is a monoclonal antibody that blocks the interleukin-31 receptor A.[1][4] Nemolizumab is humanized IgG2 monoclonal antibody that inhibits interleukin-31 signaling by binding selectively to interleukin-31 receptor alpha.[2] It is an interleukin-31 receptor antagonist.[1] IL-31 is a cytokine involved in pruritus, inflammation, epidermal dysregulation and fibrosis.[2] By inhibiting IL-31-induced responses, nemolizumab prevents the release of proinflammatory cytokines and chemokines.[2]

Nemolizumab was approved for medical use in the United States in August 2024,[4][5][6] and in the European Union in February 2025.[2][3] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]

  1. ^ a b c d "Nemluvio- nemolizumab-ilto injection, powder, lyophilized, for solution". DailyMed. 13 August 2024. Retrieved 5 September 2024.
  2. ^ a b c d e Cite error: The named reference Nemluvio EPAR was invoked but never defined (see the help page).
  3. ^ a b Cite error: The named reference Nemluvio PI was invoked but never defined (see the help page).
  4. ^ a b "Drug Trials Snapshots: Nemluvio". U.S. Food and Drug Administration (FDA). 1 October 2024. Archived from the original on 9 November 2024. Retrieved 31 October 2024. This article incorporates text from this source, which is in the public domain.
  5. ^ "Drug Approval Package: Nemluvio". U.S. Food and Drug Administration (FDA). 10 September 2024. Archived from the original on 28 September 2024. Retrieved 13 December 2024.
  6. ^ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.
  7. ^ New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.